DarioHealth announced a series of financing agreements, led by a registered direct offering expected to raise approximately $23.5 million. The offering comprises 2,437,060 common shares at $6.80 and pre-funded warrants for 1,017,499 shares at $6.7999, with closing targeted for July 23, 2026 and a 30-day issuance restriction with limited exceptions. The company engaged A.G.P./Alliance Global Partners as sole placement agent, agreeing to a 6.0% fee on most proceeds and up to $60,000 in expense reimbursements. In a concurrent insider transaction, director Dennis Matheis agreed to purchase 14,430 shares at $6.93, signaling support for the raise.
Agreement 1: DarioHealth Raises $23.5 Million in At-the-Market Registered Direct Offering of Stock and Warrants
- Agreement type: Registered direct offering of common stock and pre-funded warrants
- Counterparty: Institutional investors
- Signed / Effective: Jul 22 2026 / Jul 22 2026
- Reason: Strengthen liquidity and fund operations
Agreement 2: DarioHealth Engages A.G.P./Alliance Global Partners as Placement Agent With 6% Fee
- Agreement type: Placement agent engagement for registered direct offering
- Counterparty: A.G.P./Alliance Global Partners
- Signed / Effective: Jul 22 2026 / Jul 22 2026
- Duration / Termination: Through offering close
- Reason: Engage agent to execute the capital raise
Agreement 3: DarioHealth Director Dennis Matheis Buys 14,430 Shares at $6.93 in Concurrent Purchase
- Agreement type: Director share purchase agreement
- Counterparty: Dennis Matheis
- Signed / Effective: Jul 22 2026 / Jul 22 2026
- Reason: Insider participation alongside offering
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.